Skip to main content

SABCS 2022

News and expert insight from the 2022 San Antonio Breast Cancer Symposium

SABCS 2022 highlights

Woman taking medication

08-12-2022 | SABCS 2022 | Conference coverage | News

First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

Research news from SABCS 2022

12-12-2022 | SABCS 2022 | Conference coverage | News

Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

09-12-2022 | SABCS 2022 | Conference coverage | News

Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

09-12-2022 | SABCS 2022 | Conference coverage | News

Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

08-12-2022 | SABCS 2022 | Conference coverage | News

monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

Medicine Matters conference coverage is brought to you in partnership with medwireNews